start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=20200306
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose: The present study compared the efficacy of sunitinib and sorafenib as first-line treatment of metastatic clear cell renal cell carcinoma (mCC-RCC) with favorable or intermediate Memorial Sloan Kettering Cancer Center (MSKCC) risk.
Patients and methods: Treatment-naive patients with mCC-RCC were randomized to receive open-label sunitinib followed by sorafenib (SU/SO) or sorafenib followed by sunitinib (SO/SU). The primary endpoint was first-line progression-free survival (PFS). The secondary endpoints were total PFS and overall survival (OS).
Results: Of the 124 patients enrolled at 39 institutions from February 2010 to July 2012, 120 were evaluated. The median first-line PFS duration was 8.7 and 7.0 months in the SU/SO and SO/SU groups, respectively (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.42-1.08). The total PFS and OS were not significantly different between the SU/SO and SO/SU groups (27.8 and 22.6 months; HR, 0.73; 95% CI, 0.428-1.246; and 38.4 and 30.9 months; HR, 0.934; 95% CI, 0.588-1.485, respectively). The subgroup analysis revealed that the total PFS with SU/SO was superior to the total PFS with SO/SU in the patients with favorable MSKCC risk and those with < 5 metastatic sites). SO/SU was superior to SU/SO for patients without previous nephrectomy.
Conclusions: No statistically significant differences were found in first-line PFS, total PFS, or OS between the 2 treatment arms (ClinicalTrials.gov identifier, NCT01481870).
en-copyright=
kn-copyright=
en-aut-name=TomitaYoshihiko
en-aut-sei=Tomita
en-aut-mei=Yoshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=NaitoSei
en-aut-sei=Naito
en-aut-mei=Sei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=SassaNaoto
en-aut-sei=Sassa
en-aut-mei=Naoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=TakahashiAtsushi
en-aut-sei=Takahashi
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=KondoTsunenori
en-aut-sei=Kondo
en-aut-mei=Tsunenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=KoieTakuya
en-aut-sei=Koie
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=ObaraWataru
en-aut-sei=Obara
en-aut-mei=Wataru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=KobayashiYasuyuki
en-aut-sei=Kobayashi
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=TeishimaJun
en-aut-sei=Teishima
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=TakahashiMasayuki
en-aut-sei=Takahashi
en-aut-mei=Masayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=MatsuyamaHideyasu
en-aut-sei=Matsuyama
en-aut-mei=Hideyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=UedaTakeshi
en-aut-sei=Ueda
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=YamaguchiKenya
en-aut-sei=Yamaguchi
en-aut-mei=Kenya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
en-aut-name=KishidaTakeshi
en-aut-sei=Kishida
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=
en-aut-name=ShirokiRyoichi
en-aut-sei=Shiroki
en-aut-mei=Ryoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=
en-aut-name=SaikaTakashi
en-aut-sei=Saika
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=
en-aut-name=ShinoharaNobuo
en-aut-sei=Shinohara
en-aut-mei=Nobuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=
en-aut-name=OyaMototsugu
en-aut-sei=Oya
en-aut-mei=Mototsugu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=
en-aut-name=KanayamaHiro-omi
en-aut-sei=Kanayama
en-aut-mei=Hiro-omi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=
affil-num=1
en-affil=Department of Urology, Niigata University Graduate School of Medical and Dental Sciences
kn-affil=
affil-num=2
en-affil=Department of Urology, Yamagata University Faculty of Medicine
kn-affil=
affil-num=3
en-affil=Department of Urology, Nagoya University Graduate School of Medicine
kn-affil=
affil-num=4
en-affil=Department of Urology, Hakodate Goryoukaku Hospital
kn-affil=
affil-num=5
en-affil=Department of Urology, Tokyo Women's Medical University Medical Center East
kn-affil=
affil-num=6
en-affil=Department of Urology, Hirosaki University Graduate School of Medicine
kn-affil=
affil-num=7
en-affil=Department of Urology, Iwate Medical University
kn-affil=
affil-num=8
en-affil=Department of Urology, Okayama University Graduate School of Medicine
kn-affil=
affil-num=9
en-affil=Department of Urology, Graduate School of Biomedical Health Science, Hiroshima University
kn-affil=
affil-num=10
en-affil= Department of Urology, Tokushima University Graduate School of Biomedical Sciences
kn-affil=
affil-num=11
en-affil=Department of Urology, Yamaguchi University Graduate School of Medicine
kn-affil=
affil-num=12
en-affil= Department of Urology, Chiba Cancer Center
kn-affil=
affil-num=13
en-affil= Department of Urology, Nihon University School of Medicine
kn-affil=
affil-num=14
en-affil=Department of Urology, Kanagawa Cancer Center
kn-affil=
affil-num=15
en-affil=Department of Urology, Fujita Health University School of Medicine
kn-affil=
affil-num=16
en-affil= Department of Urology, Ehime University
kn-affil=
affil-num=17
en-affil=Department of Urology, Hokkaido University Graduate School of Medicine
kn-affil=
affil-num=18
en-affil=Department of Urology, Keio University School of Medicine
kn-affil=
affil-num=19
en-affil=Department of Urology, Tokushima University Graduate School of Biomedical Sciences
kn-affil=
en-keyword=PFS
kn-keyword=PFS
en-keyword=RCT
kn-keyword=RCT
en-keyword=Renal cell carcinoma
kn-keyword=Renal cell carcinoma
en-keyword=SO/SU
kn-keyword=SO/SU
en-keyword=SU/SO.
kn-keyword=SU/SO.
END